Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(6):427-428; doi:10.1093/jnci/95.6.427
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Rowett, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rowett, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 6, 427-428, March 19, 2003
© 2003 Oxford University Press

NEWS

Experts Question Impact of EU Directive on Research

Lewis Rowett

The first 10% of the full text of this article appears below.

The European Union (EU) Directive on Good Clinical Practice is set to be implemented in May 2003 and fully applied by May 2004. But there is some concern in the cancer community that the directive may actually hold back important clinical research.

The goal of the directive is to establish a single, harmonized legal framework for drug trials in EU member states. But Francoise Meunier, M.D., Ph.D., director general of the European Organization for Research and Treatment of Cancer (EORTC), warned that, for the directive to succeed, its implementation into national laws must take pan-European . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?